FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016043672> ?p ?o ?g. }

• W2016043672 endingPage "243" @default.
• W2016043672 startingPage "238" @default.
• W2016043672 abstract "The effect of concurrent paclitaxel and cisplatin was tested in vitro in 5 vulvar squamous cell carcinoma (SCC) cell lines (UM-SCV-1A, -2, -4 and -7 and UT-SCV-3). Chemosensitivity was tested using the 96-well plate clonogenic assay. Paclitaxel concentrations used varied between 0.4 and 1.6 nM, and cisplatin concentrations varied between 0.1 and 0.9 μg/ml. These drug concentrations are clinically achievable. Survival data were fitted to the LQ model, and the area under the curve (AUC) value was obtained with numerical integration. The type of interaction was determined by comparing the AUC ratio of the 2 drugs with the survival fraction (SF) of paclitaxel alone. With all cell lines tested the growth-inhibitory effect of simultaneous paclitaxel and cisplatin was at least additive. The effect of the tested combination on the UM-SCV-1A and UT-SCV-3 cell lines was clearly supra-additive with all paclitaxel concentrations tested, and the UM-SCV-4 and UM-SCV-7 cell lines exhibited a supra-additive effect with increasing paclitaxel concentrations. The degree of supra-additivity was dose-dependent in the UM-SCV-7 cell line with increasing synergy at higher paclitaxel doses. In the current study the combination of paclitaxel and cisplatin had a clear additive or supra-additive cytotoxic effect on the vulvar SCC cell lines, and it has been successfully used in other gynecologic malignancies; therefore concurrent paclitaxel and cisplatin also deserves further testing in clinical settings in advanced-stage vulvar carcinoma, which has a poor prognosis. © 2002 Wiley-Liss, Inc." @default.
• W2016043672 created "2016-06-24" @default.
• W2016043672 creator A5004268511 @default.
• W2016043672 creator A5017337687 @default.
• W2016043672 creator A5036410028 @default.
• W2016043672 creator A5042022974 @default.
• W2016043672 creator A5064193017 @default.
• W2016043672 creator A5074960296 @default.
• W2016043672 date "2002-05-16" @default.
• W2016043672 modified "2023-10-15" @default.
• W2016043672 title "Supra-additive effect with concurrent paclitaxel and cisplatin in vulvar squamous cell carcinoma<i>in vitro</i>" @default.
• W2016043672 cites W1723772693 @default.
• W2016043672 cites W1808173951 @default.
• W2016043672 cites W1845622004 @default.
• W2016043672 cites W1880772556 @default.
• W2016043672 cites W1964618314 @default.
• W2016043672 cites W1970857337 @default.
• W2016043672 cites W1979445325 @default.
• W2016043672 cites W1979566771 @default.
• W2016043672 cites W1982244574 @default.
• W2016043672 cites W1984446074 @default.
• W2016043672 cites W1988509828 @default.
• W2016043672 cites W1991463182 @default.
• W2016043672 cites W1993577287 @default.
• W2016043672 cites W1999748067 @default.
• W2016043672 cites W2003914447 @default.
• W2016043672 cites W2014107319 @default.
• W2016043672 cites W2020452319 @default.
• W2016043672 cites W2021728910 @default.
• W2016043672 cites W2024844244 @default.
• W2016043672 cites W2031471596 @default.
• W2016043672 cites W2035488008 @default.
• W2016043672 cites W2037605675 @default.
• W2016043672 cites W2037951950 @default.
• W2016043672 cites W2039086504 @default.
• W2016043672 cites W2049306821 @default.
• W2016043672 cites W2055571642 @default.
• W2016043672 cites W2060113787 @default.
• W2016043672 cites W2066308837 @default.
• W2016043672 cites W2067720048 @default.
• W2016043672 cites W2071819298 @default.
• W2016043672 cites W2081406767 @default.
• W2016043672 cites W2087231331 @default.
• W2016043672 cites W2095558463 @default.
• W2016043672 cites W2133541913 @default.
• W2016043672 cites W2169133611 @default.
• W2016043672 cites W4248464802 @default.
• W2016043672 doi "https://doi.org/10.1002/ijc.10472" @default.
• W2016043672 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12115575" @default.
• W2016043672 hasPublicationYear "2002" @default.
• W2016043672 type Work @default.
• W2016043672 sameAs 2016043672 @default.
• W2016043672 citedByCount "23" @default.
• W2016043672 countsByYear W20160436722012 @default.
• W2016043672 countsByYear W20160436722013 @default.
• W2016043672 countsByYear W20160436722014 @default.
• W2016043672 countsByYear W20160436722015 @default.
• W2016043672 countsByYear W20160436722016 @default.
• W2016043672 countsByYear W20160436722018 @default.
• W2016043672 countsByYear W20160436722020 @default.
• W2016043672 crossrefType "journal-article" @default.
• W2016043672 hasAuthorship W2016043672A5004268511 @default.
• W2016043672 hasAuthorship W2016043672A5017337687 @default.
• W2016043672 hasAuthorship W2016043672A5036410028 @default.
• W2016043672 hasAuthorship W2016043672A5042022974 @default.
• W2016043672 hasAuthorship W2016043672A5064193017 @default.
• W2016043672 hasAuthorship W2016043672A5074960296 @default.
• W2016043672 hasBestOaLocation W20160436721 @default.
• W2016043672 hasConcept C117262875 @default.
• W2016043672 hasConcept C126322002 @default.
• W2016043672 hasConcept C143998085 @default.
• W2016043672 hasConcept C1491633281 @default.
• W2016043672 hasConcept C185592680 @default.
• W2016043672 hasConcept C2776694085 @default.
• W2016043672 hasConcept C2777292972 @default.
• W2016043672 hasConcept C2777546739 @default.
• W2016043672 hasConcept C2778239845 @default.
• W2016043672 hasConcept C2994491419 @default.
• W2016043672 hasConcept C502942594 @default.
• W2016043672 hasConcept C54355233 @default.
• W2016043672 hasConcept C55493867 @default.
• W2016043672 hasConcept C71924100 @default.
• W2016043672 hasConcept C81885089 @default.
• W2016043672 hasConcept C86803240 @default.
• W2016043672 hasConcept C98274493 @default.
• W2016043672 hasConceptScore W2016043672C117262875 @default.
• W2016043672 hasConceptScore W2016043672C126322002 @default.
• W2016043672 hasConceptScore W2016043672C143998085 @default.
• W2016043672 hasConceptScore W2016043672C1491633281 @default.
• W2016043672 hasConceptScore W2016043672C185592680 @default.
• W2016043672 hasConceptScore W2016043672C2776694085 @default.
• W2016043672 hasConceptScore W2016043672C2777292972 @default.
• W2016043672 hasConceptScore W2016043672C2777546739 @default.
• W2016043672 hasConceptScore W2016043672C2778239845 @default.
• W2016043672 hasConceptScore W2016043672C2994491419 @default.
• W2016043672 hasConceptScore W2016043672C502942594 @default.
• W2016043672 hasConceptScore W2016043672C54355233 @default.
• W2016043672 hasConceptScore W2016043672C55493867 @default.

• next